RedHill COO Raday Gilead reports initial holdings
RedHill Biopharma’s Chief Operating Officer Raday Gilead has filed an initial Form 3 reporting his equity holdings.
Rhea-AI Filing Summary
RedHill Biopharma’s Chief Operating Officer Raday Gilead has filed an initial Form 3 reporting his equity holdings. He holds 30,758 unvested restricted share units, each linked to one American Depositary Share (ADS), and 4,537 ADSs that are convertible at any time with no expiration date.
The filing also lists several stock option grants to purchase Ordinary Shares: 250,000 and 400,000 shares with an exercise price of $5,000 per ADS, 600,000 shares at $4,870 per ADS, and 570,000 and 180,000 shares at $7,080 per ADS. Most option grants are described as fully vested and exercisable, with expirations between March 2028 and April 2031.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Raday Gilead
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Shares | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 45,370,000 contracts (Direct);
Stock Option (Right to Buy) — 2,000,000 contracts (Direct);
Ordinary Shares — 307,580,000 shares (Direct)
Footnotes (7)
- F1. Represents 30,758 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.
- F2. Represents 4,537 ADSs, which are convertible at any time, at the holder's election and have no expiration date.
- F3. Represents stock option to purchase 250,000 Ordinary Shares (equivalent to 25 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on March 21, 2028.
- F4. Represents stock option to purchase 400,000 Ordinary Shares (equivalent to 30 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029.
- F5. Represents stock option to purchase 600,000 Ordinary Shares (equivalent to 60 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on March 25, 2030.
- F6. Represents stock option to purchase 570,000 Ordinary Shares (equivalent to 57 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The 560,000 shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.
- F7. Represents stock option to purchase 180,000 Ordinary Shares (equivalent to 18 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does RedHill Biopharma (RDHL) COO Raday Gilead’s Form 3 report?
The Form 3 shows Raday Gilead’s initial beneficial ownership in RedHill Biopharma. It includes 30,758 unvested RSUs tied to ADSs, 4,537 ADSs convertible at any time, and multiple stock option grants over Ordinary Shares with specified exercise prices and expiration dates.
What are the exercise prices and expirations of RDHL COO’s stock options?
Exercise prices are stated as $5,000 or $4,870 per ADS for several grants, and $7,080 per ADS for two others. Expiration dates run from March 21, 2028 through April 28, 2031, defining the time window during which options may be exercised.
Are the stock options reported by RedHill Biopharma’s COO vested?
Footnotes explain that the shares underlying several stock options are fully vested and exercisable. For one 570,000-share grant, 560,000 shares are fully vested and exercisable. This means most of the reported option-based compensation is already available for exercise, subject to individual decisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
